REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
12.22
+1.71 (16.27%)
At close: Oct 8, 2025, 4:00 PM EDT
12.19
-0.03 (-0.25%)
After-hours: Oct 8, 2025, 7:51 PM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $21.36M in the quarter ending June 30, 2025, a decrease of -4.20%. This brings the company's revenue in the last twelve months to $155.78M, up 74.95% year-over-year. In the year 2024, REGENXBIO had annual revenue of $83.33M, down -7.66%.
Revenue (ttm)
$155.78M
Revenue Growth
+74.95%
P/S Ratio
4.01
Revenue / Employee
$441,309
Employees
353
Market Cap
617.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RGNX News
- 2 days ago - REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD - PRNewsWire
- 9 days ago - REGENXBIO Announces Presentation at the World Muscle Society - PRNewsWire
- 4 weeks ago - Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome - Seeking Alpha
- 4 weeks ago - REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome - Seeking Alpha
- 4 weeks ago - REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II - PRNewsWire
- 5 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga